Influence
July 14, 2025

Risk for metachronous advanced neoplasia in patients with a modified definition of advanced adenoma: data from the New Hampshire colonoscopy registry

Thomas Imperiale

Published in the Clinical Gastroenterology and Hepatology. Here is a link to the article.

Regenstrief Institute authors: Thomas Imperiale, M.D.

A new analysis using data from the New Hampshire Colonoscopy Registry examined the risk of metachronous advanced neoplasia (AN) and colorectal cancer (CRC) in individuals with different subtypes of advanced adenomas (AA). The study focused on comparing patients with 10–19 mm tubular adenomas (TA) to those with modified AA characteristics—high-grade dysplasia (HGD), villous histology, or TA >20 mm.

Among 35,941 adults who underwent follow-up colonoscopy ≥12 months after index screening, five groups were analyzed. Groups 4 (TAs 10–19 mm) and 5 (modified AA) demonstrated higher adjusted risk for metachronous AN compared to low-risk Groups 1–3 (Rate Ratios: 3.67 and 4.69, respectively), with overlapping confidence intervals.

However, when the outcome was restricted to modified AA, Group 5 had a significantly higher risk than Group 4 (RR=1.52; 95% CI, 1.04–2.22). Hazard ratios for CRC were also higher in Groups 4 and 5 (HR=2.44 and 3.52, respectively) compared to the low-risk reference groups, though their confidence intervals overlapped.

These findings indicate that while both larger TAs and modified AA subtypes are associated with increased AN and CRC risk, individuals with HGD, villous features, or larger adenomas may warrant particular attention. The results suggest a need for more precise risk stratification in surveillance guidelines. Further studies are recommended to refine subgroup risks within the 10–19 mm TA population.

Authors: 

Joseph C Anderson1, Todd A Mackenzie2, Lynn F Butterly3, Thomas F Imperiale4

Affiliations: 

1Geisel School of Medicine at Dartmouth, Hanover, NH; White River Junction VAMC, White River Junction VT; NH Colonoscopy Registry, Lebanon, NH. Electronic address: Joseph.Anderson@Dartmouth.edu.

2Geisel School of Medicine at Dartmouth, Hanover, NH.

3Geisel School of Medicine at Dartmouth, Hanover, NH; Department of Gastroenterology and Hepatology, DHMC, Lebanon, NH; NH Colonoscopy Registry, Lebanon, NH.

4Indiana University School of Medicine, Dept of Med., Div. of Gastro/Hep, Indianapolis, IN; Richard L. Roudebush VA Medical Center; Regenstrief Institute, Inc.

Partners

Related News

image of a doctor consulting with a patient

Scalable approach could improve early detection of cognitive impairment in primary care

Regenstrief-led study evaluates how existing health data and patient-reported information could help clinicians identify individuals who need further assessmentEarly

Christopher Callahan, MD

Regenstrief Institute scientist named next president and CEO of Regenstrief Foundation 

Longtime Regenstrief investigator and former IU Center for Aging Research director will assume Foundation leadership in summer 2027.  Christopher

Rachel Patzer, PhD, MPH

Building trust in healthcare AI through data and evidence

As artificial intelligence rapidly transforms healthcare, innovation alone is not enough. Health systems need evidence that AI tools are

doctor using electronic health record

Data expertise helps researchers understand how clinical tools are used in real-world care

Regenstrief Data Services (RDS) provided critical health data and specialized expertise to support research examining clinical decision-support use across